Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis.
BACKGROUND
The aim of this study was to compare the clinical features and proliferating cell nuclear antigen (PCNA), p53, Bcl-X, and Bax expression in primary oral basaloid squamous cell carcinoma (BSCC) and poorly differentiated squamous cell carcinoma (PDSCC) matched by stage and site and to assess the possible prognostic significance of these variables.


METHODS
Seventeen cases of oral BSCC were compared with 27 PDSCCs matched by stage and tumor site. In addition, PCNA, p53, Bax, and Bcl-X expression in both carcinomas were evaluated in relation to their clinicopathologic features and prognostic values using the Kaplan-Meier method and Cox regression models.


RESULTS
No statistically significant differences were found between the groups (BSCC and PDSCC) in regard to clinical features and immunohistochemical reactivity for antibodies PCNA, p53, and Bcl-X. In comparison with PDSCC, the BSCC group exhibited a higher Bax score (p = .031). The 5-year and 10-year overall survival, cancer-specific survival, and disease-free survival rates demonstrated no significant differences between the BSCC and PDSCC groups, and the PCNA, p53, Bax, and Bcl-X also showed no prognostic value.


CONCLUSIONS
These results suggest that the clinical and biologic course of BSCC is similar to PDSCC in the oral cavity when clinical stage and site are matched.
Sampaio-Góes
Fernanda C G
FC
Faculdade de Odontologia de Bauru, Area de Patologia, Alameda Octávio Pinheiro Brisolla, 9-75 CEP 17012-901, Bauru, São Paulo, Brazil.
Oliveira
Denise T
DT
Dorta
Regina G
RG
Nonogaki
Suely
S
Landman
Gilles
G
Nishimoto
Inês N
IN
Kowalski
Luiz P
LP
D000328:Adult; D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D018307:Neoplasms, Squamous Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis* / Q000235:genetics; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D051028:bcl-2-Associated X Protein / Q000032:analysis* / Q000235:genetics; D051020:bcl-X Protein / Q000032:analysis* / Q000235:genetics
C494826:BAX protein, human; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein